213 related articles for article (PubMed ID: 17403429)
1. GPR30: a novel indicator of poor survival for endometrial carcinoma.
Smith HO; Leslie KK; Singh M; Qualls CR; Revankar CM; Joste NE; Prossnitz ER
Am J Obstet Gynecol; 2007 Apr; 196(4):386.e1-9; discussion 386.e9-11. PubMed ID: 17403429
[TBL] [Abstract][Full Text] [Related]
2. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Arias-Pulido H; Royce M; Gong Y; Joste N; Lomo L; Lee SJ; Chaher N; Verschraegen C; Lara J; Prossnitz ER; Cristofanilli M
Breast Cancer Res Treat; 2010 Aug; 123(1):51-8. PubMed ID: 19902352
[TBL] [Abstract][Full Text] [Related]
3. GPR30 predicts poor survival for ovarian cancer.
Smith HO; Arias-Pulido H; Kuo DY; Howard T; Qualls CR; Lee SJ; Verschraegen CF; Hathaway HJ; Joste NE; Prossnitz ER
Gynecol Oncol; 2009 Sep; 114(3):465-71. PubMed ID: 19501895
[TBL] [Abstract][Full Text] [Related]
4. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.
Filardo EJ; Graeber CT; Quinn JA; Resnick MB; Giri D; DeLellis RA; Steinhoff MM; Sabo E
Clin Cancer Res; 2006 Nov; 12(21):6359-66. PubMed ID: 17085646
[TBL] [Abstract][Full Text] [Related]
5. The value of epithelial membrane antigen overexpression in hyperplastic and malignant endometrium and its relationship with steroid hormone receptor expression.
Kir G; Cetiner H; Gurbuz A; Karateke A
Eur J Gynaecol Oncol; 2004; 25(4):502-5. PubMed ID: 15285315
[TBL] [Abstract][Full Text] [Related]
6. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.
He YY; Cai B; Yang YX; Liu XL; Wan XP
Cancer Sci; 2009 Jun; 100(6):1051-61. PubMed ID: 19432902
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.
Ino Y; Akimoto T; Takasawa A; Takasawa K; Aoyama T; Ueda A; Ota M; Magara K; Tagami Y; Murata M; Hasegawa T; Saito T; Sawada N; Osanai M
Histol Histopathol; 2020 Apr; 35(4):351-359. PubMed ID: 31483053
[TBL] [Abstract][Full Text] [Related]
8. CD44 expression in papillary serous endometrial carcinoma.
Hosford S; Elliott J; Ma ZW; Majeste R; Dubeshter B
Int J Gynecol Cancer; 2003; 13(4):480-4. PubMed ID: 12911725
[TBL] [Abstract][Full Text] [Related]
9. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
[TBL] [Abstract][Full Text] [Related]
10. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
Pilka R; Mícková I; Lubuský M; Dusková M; Rícánková M; Kudela M
Ceska Gynekol; 2008 Jul; 73(4):222-7. PubMed ID: 18711961
[TBL] [Abstract][Full Text] [Related]
11. Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2.
He YY; Du GQ; Cai B; Yan Q; Zhou L; Chen XY; Lu W; Yang YX; Wan XP
J Cancer Res Clin Oncol; 2012 May; 138(5):775-83. PubMed ID: 22270964
[TBL] [Abstract][Full Text] [Related]
12. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.
Liu Q; Li JG; Zheng XY; Jin F; Dong HT
Chin Med J (Engl); 2009 Nov; 122(22):2763-9. PubMed ID: 19951611
[TBL] [Abstract][Full Text] [Related]
14. The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.
Friese K; Kost B; Vattai A; Marmé F; Kuhn C; Mahner S; Dannecker C; Jeschke U; Heublein S
J Cancer Res Clin Oncol; 2018 Jan; 144(1):13-19. PubMed ID: 28924735
[TBL] [Abstract][Full Text] [Related]
15. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.
Soong R; Knowles S; Williams KE; Hammond IG; Wysocki SJ; Iacopetta BJ
Br J Cancer; 1996 Aug; 74(4):562-7. PubMed ID: 8761370
[TBL] [Abstract][Full Text] [Related]
17. Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression.
Long L; Cao Y; Tang LD
Int J Gynecol Cancer; 2012 May; 22(4):539-45. PubMed ID: 22495744
[TBL] [Abstract][Full Text] [Related]
18. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
Wei Y; Zhang Z; Liao H; Wu L; Wu X; Zhou D; Xi X; Zhu Y; Feng Y
Oncol Rep; 2012 Feb; 27(2):504-10. PubMed ID: 22075757
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
[TBL] [Abstract][Full Text] [Related]
20. Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway.
Zhang J; Yang Y; Zhang Z; He Y; Liu Z; Yu Y; Wu S; Cai B; Feng Y
Cancer Lett; 2013 Oct; 339(2):279-87. PubMed ID: 23142288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
